(VIANEWS) – Catalyst Pharmaceuticals (CPRX), Antero Midstream Partners LP (AM), WESCO (WCC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Catalyst Pharmaceuticals (CPRX)
77.1% sales growth and 32.76% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.77.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 22.76. Meaning, the purchaser of the share is investing $22.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.76%.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $17.52 at 01:22 EST, way below its 52-week high of $22.11 and way higher than its 52-week low of $6.15.
Revenue Growth
Year-on-year quarterly revenue growth grew by 58.6%, now sitting on 214.2M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Catalyst Pharmaceuticals’s EBITDA is 54.66.
2. Antero Midstream Partners LP (AM)
11.1% sales growth and 14.57% return on equity
Antero Midstream Corporation owns and operates midstream energy assets. It owns and operates natural gas gathering pipelines, compression stations, processing and fractionation plants, and water handling and treatment assets in the Marcellus Shale and Utica Shale basins. The company was founded in 2013 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, Antero Midstream Partners LP has a trailing twelve months EPS of $0.68.
PE Ratio
Antero Midstream Partners LP has a trailing twelve months price to earnings ratio of 15.47. Meaning, the purchaser of the share is investing $15.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.57%.
Yearly Top and Bottom Value
Antero Midstream Partners LP’s stock is valued at $10.52 at 01:22 EST, under its 52-week high of $11.61 and way above its 52-week low of $8.56.
Moving Average
Antero Midstream Partners LP’s value is higher than its 50-day moving average of $10.47 and above its 200-day moving average of $10.35.
Volume
Today’s last reported volume for Antero Midstream Partners LP is 1139300 which is 57.95% below its average volume of 2709850.
3. WESCO (WCC)
7.5% sales growth and 20.96% return on equity
WESCO International, Inc. provides business-to-business distribution, logistics services, and supply chain solutions in the United States, Canada, and internationally. It operates through three segments: Electrical & Electronic Solutions (EES), Communications & Security Solutions (CSS), and Utility and Broadband Solutions (UBS). The EES segment supplies products and supply chain solutions, including electrical equipment and supplies, automation and connected devices, security, lighting, wire and cable, and safety, as well as maintenance, repair, and operating (MRO) products. This segment also offers contractor solutions, direct and indirect manufacturing supply chain optimization programs, lighting and renewables advisory services, and digital and automation solutions. The CSS segment operates in the network infrastructure and security markets. This segment sells products directly to end-users or through various channels, including data communications contractors, security, network, professional audio/visual, and systems integrators. It also provides safety and energy management solutions. The UBS segment offers products and services to investor-owned utilities; public power companies; and service and wireless providers, broadband operators, and contractors. This segment's products include wire and cables, transformers, transmission and distribution hardware, switches, protective devices, connectors, conduits, pole line hardware, racks, cabinets, safety and MRO products, and point-to-point wireless devices. This segment also offers various service solutions, including fiber project management, high and medium voltage project design and support, pre-wired meters and capacitor banks, meter testing and metering infrastructure installation, personal protective equipment dielectric testing, and tool repair, as well as emergency response, storage yard, materials, and logistics management. The company was founded in 1922 and is headquartered in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, WESCO has a trailing twelve months EPS of $15.39.
PE Ratio
WESCO has a trailing twelve months price to earnings ratio of 8.87. Meaning, the purchaser of the share is investing $8.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.96%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.6%, now sitting on 21.42B for the twelve trailing months.
Sales Growth
WESCO’s sales growth is 10% for the current quarter and 7.5% for the next.
4. Cooper Companies (COO)
6.4% sales growth and 5.26% return on equity
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Earnings Per Share
As for profitability, Cooper Companies has a trailing twelve months EPS of $7.53.
PE Ratio
Cooper Companies has a trailing twelve months price to earnings ratio of 49.51. Meaning, the purchaser of the share is investing $49.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.26%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 7.1% and positive 4.1% for the next.
